Submitted by dcc on Thu, 2019-01-03 11:33 Study Title: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)CIRB: Adult CIRB - Late Phase EmphasisLead Group: AllianceStatus: ActiveReview Status: Available to Open
